Peptide Initiative

Condition Spotlight

HIV-Associated Lipodystrophy

Antiretroviral therapy has transformed HIV into a manageable chronic condition. But many people living with HIV face an unwelcome side effect: lipodystrophy - abnormal fat distribution that's not just cosmetic. That stubborn belly fat increases your cardiovascular risk, and it doesn't respond to diet and exercise the way normal fat does.

TesamorelinGrowth Hormone
2Peptides in this guide
Week 1-4 → Long-TermTimeline
4Lifestyle areas
3Reality checks

  • Visceral Fat

    Belly fat around organs that doesn't budge

  • Facial Wasting

    Sunken cheeks and temples

  • Metabolic Risk

    Increased cardiovascular complications

Understanding Lipodystrophy

Why HIV Treatment Changes Body Fat

HIV lipodystrophy syndrome involves two related but distinct problems. Lipoatrophy means loss of fat from certain areas - typically the face, arms, legs, and buttocks, leading to a gaunt appearance. Lipohypertrophy means accumulation of fat in other areas - especially deep in the abdomen (visceral fat), behind the neck ('buffalo hump'), and in the breasts. This isn't just about appearance. Visceral abdominal fat is metabolically active tissue that increases insulin resistance, drives inflammation, and significantly raises cardiovascular risk. People with HIV already have elevated cardiovascular risk; lipodystrophy makes it worse.
The fat isn't just in the wrong place - it's the wrong kind of fat.

Older antiretroviral drugs (especially stavudine, zidovudine, and some protease inhibitors) are the main culprits. Newer regimens are less likely to cause lipodystrophy, but for those already affected, the changes can persist even after switching medications. That's where tesamorelin comes in - it's the only FDA-approved treatment specifically for this condition.

Approved 2010

Tesamorelin

The FDA-Approved Solution

A growth hormone-releasing hormone (GHRH) analog that specifically targets and reduces visceral abdominal fat in people with HIV lipodystrophy.

Its role
Telling your body to burn the dangerous belly fat it's been hoarding
Typical range
0.1-0.2 mg daily

The bottom line

Tesamorelin is the only medication FDA-approved specifically for HIV-associated lipodystrophy. It reduces visceral fat by stimulating your body's natural growth hormone release, without the problems associated with giving growth hormone directly.

Full Tesamorelin profileDosing protocol

Each peptide targets a different aspect of the condition. Together, they create a comprehensive approach.

  1. 01TesamorelinThe FDA-Approved SolutionTelling your body to burn the dangerous belly fat it's been hoarding
  2. 02Growth HormoneThe Direct ApproachDirectly replacing the hormone rather than stimulating its natural production

4 angles of attack

  • Stimulates GH Release

    Tesamorelin mimics natural GHRH, prompting your pituitary gland to release growth hormone

  • Activates Lipolysis

    Increased GH promotes breakdown of stored fat, particularly visceral adipose tissue

  • Reduces Trunk Fat

    Clinical trials show significant reduction in abdominal fat mass

  • Preserves Metabolic Function

    Unlike direct GH, tesamorelin has minimal effect on glucose tolerance

An honest breakdown based on research and clinical reports.

Phase 1 of 5

Week 1-4

Getting Started

What's happening inside

The medication is beginning to affect your GH/IGF-1 axis. Fat mobilization processes are starting, but visible changes are unlikely yet.

What you might notice

  • Getting used to daily injection routine
  • Possible injection site reactions (redness, itching) - usually mild
  • Some people notice subtle changes in how they feel
  • Labs may show increase in IGF-1 levels

Watch for

Injection site reactions are common but usually mild. Rotate sites within the abdomen. Avoid injecting into areas of lipodystrophy.

Realistic expectations

Focus on establishing the routine. Don't expect visible changes yet.

General guidelines based on research literature and clinical reports. Work with a healthcare provider experienced in peptide therapy to customize for your situation.

Important: These are general guidelines. Don't self-prescribe based on internet articles. Work with a qualified healthcare provider.

Tesamorelin · typical range

0.1-0.2mg

daily

Common protocols

  • Standard: 2 mg subcutaneous injection daily
  • Original formulation (Egrifta): Must reconstitute before each use
  • New formulation (Egrifta WR): Ready-to-use, no reconstitution needed
  • Assess response at 12 weeks - if no reduction in visceral fat, consider discontinuation

Timing considerations

  • Evening injection (before bed) aligns with natural GH surge during sleep
  • Morning injection also effective for convenience
  • Consistent timing is more important than specific time of day
  • At least 30-60 minutes from food or other medications

Cycling

Often used in longer cycles (12-16 weeks minimum) to see full benefits; can continue long-term

Practical tips

Injection basics

  • Inject into abdomen, avoiding areas of lipodystrophy or scarring
  • Rotate injection sites within the approved area
  • Original Egrifta requires reconstitution before each use - follow instructions carefully
  • Newer Egrifta WR formulation is ready-to-use
  • Let refrigerated medication sit at room temperature briefly before injection

Storage

  • Store in refrigerator (36-46°F/2-8°C)
  • Protect from light
  • Original formulation: Reconstituted solution should be used immediately
  • Do not freeze
  • Check expiration dates

Peptides work best as part of a comprehensive approach.

Exercise

Complementing Treatment

While exercise alone can't eliminate HIV-associated visceral fat, it can enhance tesamorelin's effects and provide independent cardiovascular benefits.

The basics that matter

Aerobic exercise
Regular cardio (walking, cycling, swimming) improves cardiovascular fitness and helps with overall metabolic health.
Resistance training
Weight training builds lean mass, which improves metabolic rate and insulin sensitivity.
Consistency over intensity
Regular moderate exercise is more sustainable and effective than sporadic intense sessions.

Condition-specific tips

  • Exercise alone typically doesn't resolve HIV lipodystrophy, but supports overall health
  • Building muscle mass can help improve body composition ratios
  • Cardio exercise has independent cardiovascular benefits important for this population
  • Start gradually if you haven't been active - build up over time

What to keep in mind.

  • Not for Facial Wasting

    Tesamorelin specifically targets visceral abdominal fat. It does NOT treat facial lipoatrophy (facial wasting). Facial filling procedures are the treatment for that aspect of lipodystrophy.

  • Not Everyone Responds

    About 50% of patients achieve significant trunk fat reduction. If you don't respond by 12 weeks, continued treatment may not be beneficial. Response should be assessed.

  • Benefits Reverse Without Treatment

    Visceral fat typically reaccumulates within months of stopping tesamorelin. This is a long-term treatment for most people who respond.

This information is for educational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before starting any new treatment.

PeptideWhat it doesTypical doseTiming
TesamorelinThe FDA-Approved Solution0.1-0.2 mg dailyEvening injection (before bed) aligns with natural GH surge during sleep
Growth HormoneThe Direct ApproachVaries by protocol; typically lower doses than for GH deficiencyTypically administered in the evening or before bed

Early wins to watch

  • Injection routine established
  • Possible subtle energy improvements
  • IGF-1 levels responding
  • No significant side effects

Support stack

  • Heart-healthy diet
  • Regular exercise (cardio + strength)
  • Cardiovascular risk management
  • ART optimization
  • Mental health support

Lifestyle priorities

  1. 1Consistent daily injection
  2. 2Regular physical activity
  3. 3Heart-healthy nutrition
  4. 4Comprehensive HIV care
  5. 5Cardiovascular risk factor management

HIV lipodystrophy is a real medical condition, not just a cosmetic concern. The excess visceral fat increases your cardiovascular risk in a population already at elevated risk. Tesamorelin offers a targeted, FDA-approved approach to reducing this dangerous fat.

Work closely with your HIV care team to integrate tesamorelin into your overall health management. It's one important tool in maintaining your health and quality of life while living with HIV.

0.1-0.2 mg dailyTesamorelin · typical range in this guide
Open the Tesamorelin calculatorTesamorelin calculator